Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligome

Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21.Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7.Some patients achieved complete resolution of pruritus within the 21-day period.HT-001 was well tolerated, with no treatment-related serious adverse events reported.NEW YORK, April 15, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a biopharmaceutical company focuse

NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD). The research collaboration is le

Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology. NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ, in improving cognitive function and reducing neuroinflammation in Alzheimer's disease (AD). HT-ALZ, a proprietary formulation of an FDA-approved NK-1 receptor antagonist, has shown si

NEW YORK, March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of HT-001, the Company's lead clinical asset. This newly filed application seeks to expand the Company's intellectual property portfolio surrounding HT-001 and builds upon Hoth's already approved patent for the compound. The formulation-specific filing

NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-KIT. The Company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ—genes implicated in allergic inflammation and mast cell-related diseases. These refined claims e

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays. Marked Tumor Volume Reduction in GIST Mouse Models – In a humanized xenograft model, HT-KIT treatment (12.5 mg/kg IV every three days) led to a significant reduction in tumor growth, with di

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as "compassionate use." NEW YORK, March 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for t

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel, trastuzumab, and pertuzumab. The patient developed pruritic, burning red papules on the face, scalp, and upper back, a known dermatologic side effect of EGFR inhibitors. After just one week of applying HT-001 2% cream twice daily, the patient experienced full symptom and lesion

Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy ExpenditureHoth is developing this therapeutic in Partnership with the Department of Veterans AffairsKey Findings from the Study: Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat st

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)